Sun Pharmaceutical Industries has reported financials for the third quarter ending December 31, 2021. In Q3FY22, the consolidated sales from operations was at Rs 98,142 million, growth of 11 per cent over Q3 last year. The India formulation sales was at Rs 31,676 million, up 15 per cent over the same quarter last year. The US formulation sales was at $ 397 million, a growth of 6 per cent over Q3 last year. The Emerging Markets formulation sales was at $239 million, up by 17 per cent over Q3 last year. The Rest of World formulation sales was at $181 million, up by 3 per cent over same quarter last year. The R&D investments was at Rs 5,471 million compared to Rs 5,595 million for Q3FY21. The EBITDA was at Rs 25,574 million, up by about 8 per cent over Q3 last year, with EBITDA margin at 26.1 per cent. The net profit for the quarter was at Rs 20,588 million, up 11 per cent YoY. 

In 9mFY22, the consolidated sales from operations was at Rs 290,403 million, a growth of 17 per cent over the same period last year. EBITDA wa at Rs 78,900 million up about 27 per cent over 9m last year, with EBITDA margin at 27.2 per cent.